Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vanda Pharmaceuticals stock | $18.15

Learn how to easily invest in Vanda Pharmaceuticals stock.

Vanda Pharmaceuticals Inc is a biotechnology business based in the US. Vanda Pharmaceuticals shares (VNDA) are listed on the NASDAQ and all prices are listed in US Dollars. Vanda Pharmaceuticals employs 292 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vanda Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VNDA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vanda Pharmaceuticals stock price (NASDAQ: VNDA)

Use our graph to track the performance of VNDA stocks over time.

Vanda Pharmaceuticals shares at a glance

Information last updated 2021-10-24.
Latest market close$18.15
52-week range$10.07 - $21.86
50-day moving average $17.38
200-day moving average $17.78
Wall St. target price$24.00
PE ratio 32.049
Dividend yield N/A (0%)
Earnings per share (TTM) $0.57

Buy Vanda Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vanda Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vanda Pharmaceuticals price performance over time

Historical closes compared with the close of $18.15 from 2021-10-25

1 week (2021-10-20) 1.91%
1 month (2021-09-27) 3.24%
3 months (2021-07-27) -5.96%
6 months (2021-04-27) 7.65%
1 year (2020-10-26) 74.02%
2 years (2019-10-25) 29.27%
3 years (2018-10-26) 20.51
5 years (2016-10-26) 19.80%

Is Vanda Pharmaceuticals under- or over-valued?

Valuing Vanda Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vanda Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vanda Pharmaceuticals's P/E ratio

Vanda Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Vanda Pharmaceuticals shares trade at around 32x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Vanda Pharmaceuticals's EBITDA

Vanda Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.8 million.

The EBITDA is a measure of a Vanda Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Vanda Pharmaceuticals financials

Revenue TTM $258.5 million
Operating margin TTM 15.82%
Gross profit TTM $224.8 million
Return on assets TTM 4.76%
Return on equity TTM 7.11%
Profit margin 12.55%
Book value $8.65
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Vanda Pharmaceuticals shares

There are currently 4.7 million Vanda Pharmaceuticals shares held short by investors – that's known as Vanda Pharmaceuticals's "short interest". This figure is 0.5% down from 4.7 million last month.

There are a few different ways that this level of interest in shorting Vanda Pharmaceuticals shares can be evaluated.

Vanda Pharmaceuticals's "short interest ratio" (SIR)

Vanda Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Vanda Pharmaceuticals shares currently shorted divided by the average quantity of Vanda Pharmaceuticals shares traded daily (recently around 320277.88331072). Vanda Pharmaceuticals's SIR currently stands at 14.74. In other words for every 100,000 Vanda Pharmaceuticals shares traded daily on the market, roughly 14740 shares are currently held short.

However Vanda Pharmaceuticals's short interest can also be evaluated against the total number of Vanda Pharmaceuticals shares, or, against the total number of tradable Vanda Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vanda Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Vanda Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.106% of the tradable shares (for every 100,000 tradable Vanda Pharmaceuticals shares, roughly 106 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vanda Pharmaceuticals.

Find out more about how you can short Vanda Pharmaceuticals stock.

Vanda Pharmaceuticals share dividends

We're not expecting Vanda Pharmaceuticals to pay a dividend over the next 12 months.

Vanda Pharmaceuticals share price volatility

Over the last 12 months, Vanda Pharmaceuticals's shares have ranged in value from as little as $10.07 up to $21.86. A popular way to gauge a stock's volatility is its "beta".

VNDA.US volatility(beta: 0.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vanda Pharmaceuticals's is 0.5026. This would suggest that Vanda Pharmaceuticals's shares are less volatile than average (for this exchange).

Vanda Pharmaceuticals overview

Vanda Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc.

Frequently asked questions

What percentage of Vanda Pharmaceuticals is owned by insiders or institutions?
Currently 2.607% of Vanda Pharmaceuticals shares are held by insiders and 102.31% by institutions.
How many people work for Vanda Pharmaceuticals?
Latest data suggests 292 work at Vanda Pharmaceuticals.
When does the fiscal year end for Vanda Pharmaceuticals?
Vanda Pharmaceuticals's fiscal year ends in December.
Where is Vanda Pharmaceuticals based?
Vanda Pharmaceuticals's address is: 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
What is Vanda Pharmaceuticals's ISIN number?
Vanda Pharmaceuticals's international securities identification number is: US9216591084
What is Vanda Pharmaceuticals's CUSIP number?
Vanda Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 921659108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site